PB 9 of 2020
National Health (Originator Brand) Amendment Determination 2020 (No. 1)
National Health Act 1953
I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.
Dated 29 January 2020
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
(1) This Determination is the National Health (Originator Brand) Amendment Determination 2020 (No. 1).
(2) This Determination may also be cited as PB 9 of 2020.
This Determination commences on 1 February 2020.
3 Amendments to PB 100 of 2015
Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).
Schedule 1 Amendments
(section 3)
[1] Schedule 1, (table item 80)
Repeal the items:
80 | Exemestane | Aromasin |
|
|
80A | Ezetimibe | Ezetrol |
|
|
80B | Ezetimibe and rosuvastatin | Rosuzet Composite Pack |
|
|
80C | Ezetimibe with simvastatin | Vytorin |
|
|
Substitute:
80 | Exemestane | Aromasin |
|
|
80A | Ezetimibe | Ezetrol |
|
|
80B | Ezetimibe and rosuvastatin | Rosuzet Composite Pack |
|
|
80C | Ezetimibe with atorvastatin | Atozet |
|
|
80D | Ezetimibe with simvastatin | Vytorin |
|
|
[2] Schedule 1, (after table item 228)
Insert:
228A | Tiotropium | Spiriva Spiriva Respimat |
|
|